ASCO-2015: naibolee vazhnye klinicheskie issledovaniya
- 作者: Meshcheryakov A.A1
-
隶属关系:
- 期: 编号 18 (2015)
- 页面: 35-39
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/288290
- ID: 288290
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
In 2015, the annual conference of the American Society of Clinical Oncology (ASCO - American Society of Clinical Oncology) presented the results of new clinical trials. The most significant clinical data, according to tradition, have been reported during the plenary and special sessions. The results of these studies are usually available only in the conference. The most important and interesting data presented at ASCO in 2015 are discussed in this article.
全文:
参考
- Wolchok J.D., Chiarion-Sileni V., Gonzalez R., et al. Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). ASCO 2015:LBA001.
- Larkin J, Chiarion-Sileni V., Gonzalez R., Grob J.J., Cowey C.L., Lao C.D., Schadendorf D., Dummer R., Smylie M., Rutkowski P., Ferrucci P.F., Hill A., Wagstaff J, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. 2015;373(1):23-34.
- Brown P. D., et al. NCCTG N05 74 (Alliance): a phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. ASCO 2015:LBA003.
- Brahmer J, Reckamp K.L., Baas P., Crino L., Eberhardt W.E., Poddubskaya E., Antonia S., Pluzanski A., Vokes EE, Holgado E, Waterhouse D., Ready N., Gainor J., Aren Frontera О., Havel L, Steins M., Garassino M.C., Aerts J.G., Domine М., Paz-Ares L., Reck M., Baudelet C., Harbison C.T., Lestini B., Spigel D.R. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015;373(2):123-35
- Paz-Ares L. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advancednon-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). ASCO 2015: LBA109.
- Margolese R.G., et al. NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. ASCO 2015:LBA500.
- Turner N.C., et al. PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptorpositive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. ASCO 2015:LBA502.
- Turner N.C., Ro J., Andre F., Loi S., Verma S., Iwata H., Harbeck N., Loibl S., Huang Bartlett C., Zhang K., Giorgetti C., Randolph S., Koehler M., Cristofanilli M. Palbocidib in Hormone-Receptor-Positive Advanced Breast Cancer. N. Engl. J. Med. 2015;3 73(3):209-19.
- Le D.T., et al. PD-1 blockade in tumors with mismatch repair deficiency. ASCO 2015: LBA 100.
- Le D.T., Uram J.N., Wang H., Bartlett B.R., Kemberling H., Eyring A.D., Skora A.D., Luber B.S., Azad N.S., Laheru D., Biedrzycki B., Donehower R.C., Zaheer A., Fisher G.A., et al. PD-1 blockade in tumors with mismatch repair deficiency. N. Engl. J. Med. 2015;372 (26):2509-20.
- El-Khoueiry A.B., et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. ASCO 2015:LBA101.
- Sandler H.M. A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, highrisk prostate cancer (RTOG 0521). ASCO 2015: LBA5002.
- Seiwert T. Y. Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. ASCO 2015:LBA 6008.
- Schöffski P. Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). ASCO 2015:LBA 10502.
补充文件
